Vivos Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| V-Co Investors 3 LLC | 19.9% | 1,353,625 | SCHEDULE 13D, 2026-04-02 | 2026-03-31 |
| V-Co Investors 4 LLC | 19.9% | 86,979 | SCHEDULE 13D, 2026-07-15 | 2026-06-30 |
| Dawei Luo | 8.52% | 572,016 | SCHEDULE 13G, 2025-07-14 | 2025-07-08 |
| Armistice Capital, LLC | 4.99% | 729,755 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Streeterville Capital LLC | 0.6% | 122,963 | SCHEDULE 13G/A, 2026-09-03 | 2026-09-03 |
Purpose of Transaction (Item 4)
V-Co Investors 3 LLC
The Reporting Person's purpose of acquiring these securities is for investment purposes. The Reporting Person intends to engage, or has engaged, in discussions with the Issuer and its management and/or board of directors regarding the Issuer's financial performance, strategic direction, operational matters, and corporate governance practices. On March 31, 2026, the Issuer and V-Co 3 entered into a Securities Purchase Agreement where the Issuer sold to V-Co 3 in a private placement: (i) 1,353,625 shares of Common Stock ("PIPE Common Stock"), (ii) a Series A Common Stock Purchase Warrant ("Series A Warrant") to purchase up to 1,783,582 shares of Common Stock ("Warrant Shares"), (iii) a Series B Common Stock Purchase Warrant ("Series B Purchase Warrant" and together with the Series A Warrant, the "Common Stock Warrants") to purchase up to 1,783,582 Warrant Shares and (iv) a Pre-Funded Warrant ("Pre-Funded Warrant") to purchase up to 429,957 shares of Common Stock ("PFW Shares," together with the PIPE Common Stock and Warrant Shares, the "Shares"). In compliance with the listing rules of the Nasdaq Stock Market LLC, V-Co 3 purchased the Shares at a purchase price of $1.34 per share. The Series A Warrant is immediately exercisable with a two-year term from the date of purchase and has an exercise price of $1.09 per share. The Series B Warrant is immediately exercisable with a five-year term from the date of purchase and has an exercise price of $1.09 per share. Similarly, the …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-02; the filing has the rest
V-Co Investors 4 LLC
The Reporting Person's purpose of acquiring these securities is for investment purposes. The Reporting Person intends to engage, or has engaged, in discussions with the Issuer and its management and/or board of directors regarding the Issuer's financial performance, strategic direction, operational matters, and corporate governance practices. On June 30, 2026, the Issuer and V-Co 4 entered into a Securities Purchase Agreement where the Issuer sold to V-Co 4 in a private placement: (i) 2,749,330 shares of Series A Convertible Preferred Stock ("Convertible Preferred Stock"), and (ii) a Common Stock Purchase Warrant ("Common Stock Warrant") to purchase up to 2,749,330 shares of Common Stock ("Warrant Shares"). In compliance with the listing rules of the Nasdaq Stock Market LLC, V-Co 4 purchased the Shares at a purchase price of $0.582 per share. The Common Stock Warrant is immediately exercisable with a five-year term from the date of purchase and has an exercise price of $0.456 per share. V-Co 4 is prohibited from converting such Convertible Preferred Stock and exercising such Common Stock Warrants if it results in V-Co 4 or its affiliates owning in excess of 19.99% of the then outstanding Common Stock of the Issuer. Accordingly, for purposes of this Schedule 13D, only 86,979 of the shares of Common Stock underlying the Convertible Preferred Stock and Common Stock Warrant purchased by V-Co 4 in the private placement are deemed to be beneficially owned by V-Co 4. See Item 5 …The first part of Item 4 of the SCHEDULE 13D filed 2026-07-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-14 | Dawei Luo | 8.52% | SCHEDULE 13G |
| 2026-04-02 | V-Co Investors 3 LLC | 19.9% | SCHEDULE 13D |
| 2026-05-15 | Armistice Capital, LLC | 8.27% | SCHEDULE 13G |
| 2026-07-15 | V-Co Investors 4 LLC | 19.9% | SCHEDULE 13D |
| 2026-08-11 | Streeterville Capital LLC | 9.3% | SCHEDULE 13G |
| 2026-08-14 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-09-03 | Streeterville Capital LLC | 0.6% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Vivos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.